Key result
Cangrelor adverse event reports reveal unexpected cardiac arrest and failure, with ~35% linked to PCI.
Why the study?
Real-world safety data on cangrelor used to reduce thrombotic events in adults undergoing PCI is limited.
What are the real-world adverse events associated with cangrelor use reported in the FAERS database?
Observational (n=163)
What are the real-world adverse events associated with cangrelor use reported in the FAERS database?
Real-world pharmacovigilance data reveals unexpected adverse events for cangrelor, such as cardiac arrest and heart failure, and highlights significant off-label use.
Answers are grounded in this paper and cite their sources.
FAERS signals for unexpected cardiac events with cangrelor require prospective confirmation; should not yet alter practice or labeling.
BACKGROUND: Cangrelor is used to reduce thrombotic events in adults undergoing percutaneous coronary intervention, but real-world safety data is limited. This study analyzes adverse events (AEs) related to cangrelor using the FDA adverse event reporting system (FAERS) database. METHODS: We employed statistical techniques such as the reporting odds ratio, proportional reporting ratio, bayesian confidence propagation neural network, and multi-item gamma poisson shrinker to analyze the data from the FAERS database. Several unexpected AEs not listed in the drug labeling emerged, including cardiac arrest, and cardiac failure. Although percutaneous coronary intervention was the most common indication (35.4%), numerous events were associated with off-label use, particularly for conditions such as acute myocardial infarction, antiplatelet therapy, and anticoagulant therapy. CONCLUSION: Our research reveals both anticipated and unexpected AEs, providing important new information on the safety profile of cangrelor. Furthermore, we have discovered certain problems pertaining to product applications. It is recommended that manufacturers clearly highlight indications and usage instructions, and medical personnel closely follow drug administration protocols.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted an observational in Adverse events related to cangrelor (n=163). Cangrelor was evaluated on Adverse events (AEs). Analysis of cangrelor adverse event reports revealed unexpected events including cardiac arrest and cardiac failure, with 35.4% of events linked to percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: